Corcept Therapeutics, Inc. (CORT)

Oncology Corporate Profile

Stock Performance

10.6500
0.0000

HQ Location

149 Commonwealth Drive
Menlo Park, CA 94025

Company Description

Corcept is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, oncologic and psychiatric disorders. Korlym, a first generation competitive GR antagonist, is the company’s first FDA-approved medication.

Website: http://www.corcept.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
mifepristoneprogesterone receptor antagonistBreast cancerI
mifepristone (+ eribulin)progesterone receptor antagonistBreast cancerI

View additional information on product candidates here »

Source


http://www.corcept.com

Recent News Headlines

Today's Research Reports on Stocks to Watch: Array Biopharma and Corcept Therapeutics

3/17/2017 01:03 pm

[Accesswire] - NEW YORK, NY / ACCESSWIRE / March 17, 2017 / Array Biopharma and Corcept Therapeutics are two companies whose stock prices both fell on Thursday, following the trend of the general market. Both stocks ...

Corcept Therapeutics to Announce Preliminary 2016 Financial Results, Provide 2017 Revenue Guidance and Corporate Update, and Host Conference Call

1/23/2017 09:00 pm

[Marketwired] - Corcept Therapeutics Incorporated today announced it will report preliminary fourth quarter and full year 2016 financial results and provide 2017 revenue guidance and a corporate update on January 30, ...

Corcept Therapeutics Announces Encouraging Results of Phase 1/2 Trial of Mifepristone Plus Eribulin in Triple-Negative Breast Cancer

12/10/2016 01:03 pm

[Marketwired] - Corcept Therapeutics Incorporated , a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, psychiatric and oncologic disorders by modulating ...